Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage
Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases. The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination of individuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 2, 2013 | Grant | — | 1 | The Institute for the Promotion of Innovation by Science and Technology in Flanders | — | Detail |
Nov 3, 2008 | Series A | €8.50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
The Institute for the Promotion of Innovation by Science and Technology in Flanders | Yes | Grant |
Vinnof | — | Series A |